M. Pietanza

发表

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

M. Kris, C. Azzoli, W. Pao, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of CT volumetric measurement with RECIST response in patients with lung cancer.

M. Kris, C. Moskowitz, M. Ginsberg, 2016, European journal of radiology.

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

A. Tafreshi, J. Riess, M. Pietanza, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events.

E. Basch, A. Bennett, M. Pietanza, 2011, Journal of the National Cancer Institute.

Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation.

K. Rosenzweig, C. Rudin, M. Pietanza, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.

A. Lash, L. Schwartz, Binsheng Zhao, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stage IV Lung Carcinoids: Spectrum and Evolution of Proliferation Rate, Focusing on Variants with Elevated Proliferation Indices

M. Ladanyi, C. Rudin, W. Travis, 2019, Modern Pathology.

Large Cell Neuroendocrine Carcinoma

W. Travis, M. Pietanza, I. Sarkaria, 2012 .

Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience.

C. Sima, V. Rusch, G. Sica, 2011, The Annals of thoracic surgery.

Phase II Study of a Non‐Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas

A. Lash, L. Schwartz, M. Kris, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.

A. Drilon, C. Sima, M. Zauderer, 2014, Lung cancer.

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

C. Sima, M. Kris, C. Azzoli, 2012, Clinical Cancer Research.

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

S. Novello, E. Felip, E. Esteban, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer

M. Kris, C. Azzoli, A. Holodny, 2010, Journal of Neuro-Oncology.

Using a Population-Based Analysis to Determine the Management and Treatment of Early-Stage Small-Cell Lung Cancer.

M. Pietanza, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Case Series of Dose-Limiting Peripheral Edema Observed in Patients Treated with Pemetrexed

M. Kris, C. Azzoli, N. Rizvi, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Kidney tubular toxicity of maintenance pemetrexed therapy.

M. Pietanza, S. Seshan, Vincent Miller, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data

V. Velcheti, M. Pietanza, Xiaohan Hu, 2022, Cancers.

Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy.

M. Zauderer, M. Pietanza, L. Krug, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)

C. Rudin, R. Govindan, R. Salgia, 2015 .

Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

A. Chiang, L. Hart, M. Pietanza, 2015 .

Bringing the genomic landscape of small-cell lung cancer into focus

Marc Ladanyi, M. Ladanyi, M. Pietanza, 2012, Nature Genetics.

Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial

C. Sima, M. Kris, E. Basch, 2016, Clinical trials.

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer

K. Offit, J. Vijai, M. Robson, 2012, Cancer.

KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).

C. Rudin, S. Peters, A. Navarro, 2020 .

Prognostic Value of Pre radiotherapy 18 F-FDG PET/CT Volumetrics in Limited-stage Small Cell Lung Cancer

K. Rosenzweig, M. Pietanza, A. Rimner, 2016 .

Durable, exceptional response to temozolomide in a patient with extensive-stage small cell lung cancer (ES-SCLC) metastatic to brain

L. Byers, M. Pietanza, P. D. Groot, 2017 .

P2.04-007 KEYNOTE-604: Phase 3 Randomized, Double-Blind Trial of Pembrolizumab/Placebo plus Etoposide/Platinum for Extensive Stage-SCLC

C. Rudin, M. Pietanza, L. Shen, 2017 .

Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189.

E. Felip, E. Esteban, M. Pietanza, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence of Pneumonitis Among Limited Stage Small Cell Lung Cancer Patients Exposed to Concurrent Chemoradiation: A Systematic Literature Review and Meta-Analysis.

M. Pietanza, A. Deitz, J. Uyei, 2021, Clinical lung cancer.

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407

A. Tafreshi, L. Paz-Ares, M. Pietanza, 2019, Annals of Oncology.

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

D. Jäger, P. Ascierto, P. Ott, 2015, Journal of Immunotherapy for Cancer.

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

E. Felip, E. Esteban, M. Pietanza, 2020, The Lancet. Oncology.

Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

J. Lunceford, M. Ayers, R. Herbst, 2019, Annals of Oncology.

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

J. Lunceford, M. Ayers, B. Halmos, 2022, JTO clinical and research reports.

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib

H. Wakelee, T. Lynch, V. Miller, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

E. Felip, M. Pietanza, S. Gadgeel, 2018 .

LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

J. Lunceford, M. Ayers, R. Herbst, 2019 .

In Reply to ‘Secondary Capillary Leak Syndrome Related to Pemetrexed Exposure’

M. Pietanza, I. Glezerman, 2012 .

Small cell lung cancer (SCLC) among patients who are never smokers.

M. Berger, C. Sima, M. Kris, 2013 .

OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

J. Lunceford, M. Ayers, E. Felip, 2019, Journal of Thoracic Oncology.

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

J. Lunceford, M. Ayers, L. Sequist, 2019, Journal of Thoracic Oncology.

A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers.

C. Sima, M. Kris, Gregory Riely, 2015 .

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.

Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets

N. Socci, M. Ladanyi, M. Berger, 2016, Clinical Cancer Research.

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

C. Rudin, M. Kris, I. Wistuba, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

M. Kris, J. Hsieh, E. Cheng, 2017, Nature Communications.

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling

M. Ladanyi, C. Sima, M. Kris, 2011, Molecular Cancer Therapeutics.

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC.

J. Lunceford, M. Ayers, T. Mok, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?

C. Rudin, J. Minna, L. Byers, 2015, Clinical Cancer Research.

小细胞肺癌的的分子发病机制

M. Pietanza, S. D’Angelo, M. Catherine PIETANZA, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

The molecular pathogenesis of small cell lung cancer

M. Pietanza, S. D’Angelo, 2010, Cancer biology & therapy.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

G. Giaccone, M. Krasnow, C. Rudin, 2022 .

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

C. Rudin, R. Govindan, Melissa L. Johnson, 2017, The Lancet. Oncology.

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

C. Rudin, W. Travis, P. Massion, 2015, Science Translational Medicine.

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.

G. Giaccone, C. Rudin, Nofisat Ismaila, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

C. Sima, M. Kris, C. Azzoli, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Defining the immunologic phenotype of thymic epithelial tumors.

C. Sima, J. Wolchok, Gregory Riely, 2015 .

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

C. Sima, C. Rudin, M. Kris, 2016, Clinical lung cancer.

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

C. Rudin, S. Peters, A. Navarro, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.

E. Felip, E. Esteban, M. Pietanza, 2019, Journal of Clinical Oncology.

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

William Pao, Maria E Arcila, Gregory J Riely, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Michael Thomas, Yi-long Wu, E. Felip, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

J. Lunceford, M. Ayers, Ying Cheng, 2019, Annals of Oncology.

EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib

X. Chen, A. Viale, M. Kris, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.

M. Berger, C. Rudin, M. Kris, 2016, Lung cancer.

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1

V. Velcheti, M. Pietanza, Xiaohan Hu, 2022, Frontiers in Oncology.

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Ying Cheng, B. Halmos, H. Borghaei, 2020, Cancer.

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

A. Tafreshi, M. Pietanza, M. O'Brien, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer

A. Pickard, M. Pietanza, T. Burke, 2018, PharmacoEconomics.

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

M. Kris, C. Azzoli, W. Pao, 2011, Clinical Cancer Research.

Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer

M. Kris, C. Azzoli, T. Lynch, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bronchial and Thymic Carcinoid Tumors.

M. Pietanza, A. Litvak, 2016, Hematology/oncology clinics of North America.

Complementary therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

L. Jones, M. Pietanza, Nagi B. Kumar, 2013, Chest.

Novel therapeutic approaches for small cell lung cancer: the future has arrived.

C. Rudin, M. Pietanza, 2012, Current problems in cancer.

LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

A. Tafreshi, J. Riess, M. Pietanza, 2020 .

First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment.

V. Velcheti, M. Pietanza, T. Burke, 2019, Immunotherapy.

A phase 2 study of the insulin‐like growth factor‐1 receptor inhibitor MK‐0646 in patients with metastatic, well‐differentiated neuroendocrine tumors

Laura H. Tang, D. Solit, E. Vakiani, 2012, Cancer.

Long-term quality of life and neuropsychologic functioning for patients with CNS germ-cell tumors: from the First International CNS Germ-Cell Tumor Study.

H. Weiner, M. Pietanza, J. Finlay, 2001, Neuro-oncology.

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.

A. Tafreshi, Ying Cheng, L. Paz-Ares, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology

M. Suarez‐Almazor, M. Atkins, M. Pietanza, 2023, Journal for ImmunoTherapy of Cancer.

Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.

Michael P. Morrissey, M. Ayers, E. Felip, 2020 .

Structure-Activity Studies on the Abl-SH2 Domain

T. Muir, M. Pietanza, 2002 .

Phase II trial of bortezomib in KRAS G12D mutant lung cancers.

A. Drilon, M. Kris, Gregory Riely, 2015 .

Seeking New Approaches to Patients With Small Cell Lung Cancer.

S. Peters, M. Pietanza, W. Curran, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

Small cell and neuroendocrine tumors of the lung

C. Rudin, M. Kris, W. Travis, 2015 .

OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%

A. Tafreshi, M. Pietanza, M. O'Brien, 2017 .

Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes

M. Ladanyi, M. Berger, M. Kris, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract CT084: Relationship betweenSTK11andKEAP1mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC

J. Lunceford, M. Ayers, T. Mok, 2020, Tumor Biology.

ORAL02.01: Safety and Efficacy of Single‐Agent Rovalpituzumab Tesirine, a DLL3‐Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology

C. Rudin, R. Govindan, L. Byers, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.

C. Rudin, M. Kris, W. Travis, 2011, Lung cancer.

KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC

J. Lunceford, M. Ayers, E. Felip, 2019 .

Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices.

V. Velcheti, M. Pietanza, B. Piperdi, 2019, Immunotherapy.

EGFR mutations in men and cigarette smokers with lung adenocarcinoma.

M. Ladanyi, M. Kris, V. Rusch, 2010 .

A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs).

C. Rudin, M. Kris, I. Wistuba, 2016 .

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.

A. Drilon, C. Sima, M. Kris, 2012 .

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

E. Felip, E. Esteban, M. Pietanza, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

A. Tafreshi, Ying Cheng, B. Halmos, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.

P. Ascierto, P. Ott, M. Pietanza, 2015 .

1535TiPKEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)

C. Rudin, M. Pietanza, L. Shen, 2017 .

O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC

E. Felip, E. Esteban, M. Pietanza, 2019, Journal of Thoracic Oncology.

KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?

E. Felip, E. Esteban, M. Pietanza, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Complementary Therapies and Integrative Medicine in Lung Cancer

L. Jones, M. Pietanza, Nagi B. Kumar, 2013 .

Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC

S. Novello, E. Felip, E. Esteban, 2018, Clinical Trials.

Assessing changes in tumor size with CT scans in lung cancer: are volumetric measurements better than unidimensional (1D) and bidimensional (2D) assessments?

L. Schwartz, Binsheng Zhao, M. Kris, 2008 .

MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial

C. Rudin, M. Kris, Jing Wang, 2017 .

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

M. Kris, C. Azzoli, W. Pao, 2011, Journal of Thoracic Oncology.

H. Wakelee, V. Miller, M. Pietanza, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes

M. Ladanyi, M. Berger, M. Kris, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia.

Jie Yang, M. Pietanza, He-long Zhang, 2023, Immunotherapy.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

M. Krasnow, J. Minna, P. Massion, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer

M. Pietanza, T. Steiniche, A. Deitz, 2024, Frontiers in oncology.

1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC

C. Rudin, M. Pietanza, J. Mazières, 2020 .

Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations

M. Pietanza, M. Garassino, H. Aggarwal, 2023, JTO clinical and research reports.

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling

M. Ladanyi, C. Sima, M. Kris, 2011, Molecular Cancer Therapeutics.

Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

M. Kris, C. Azzoli, W. Pao, 2010 .

Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients

M. Pietanza, D. Bajorin, J. Brahmer, 2024, European journal of cancer.